Skip to main content
logo
Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
22.99
-0.35 (-1.50%)
Oct 2, 2026, 4:00 PM EDT - Market closed

Nurix Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Dec - Nov.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Market Capitalization
2,3861,7921,5663025841,286
Market Cap Growth
232.02%14.43%419.13%-48.35%-54.57%-22.36%
Enterprise Value
2,0011,4201,13641184942
Last Close Price
22.9917.6822.116.2212.3928.82

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
PS Ratio
64.9021.3428.713.9215.1243.22
PB Ratio
5.923.332.971.511.923.76
P/TBV Ratio
5.933.332.971.511.923.76

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
EV/Sales Ratio
54.4116.9120.820.534.7631.66

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Debt / Equity Ratio
0.140.100.050.150.040.04
Net Debt / Equity Ratio
-0.96-1.00-1.10-1.32-1.19-1.23
Net Debt / EBITDA Ratio
1.091.942.841.782.013.62
Net Debt / FCF Ratio
1.272.043.202.952.104.66
Asset Turnover
0.070.120.110.200.090.07
Quick Ratio
6.196.876.383.324.394.57
Current Ratio
6.347.026.463.404.514.70
Return on Equity (ROE)
-80.30%-49.63%-53.22%-57.10%-55.84%-37.05%
Return on Assets (ROA)
-40.06%-26.30%-25.98%-25.10%-25.72%-16.88%
Return on Capital Employed (ROCE)
-77.90%-47.50%-37.10%-57.70%-53.10%-28.70%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Earnings Yield
-14.31%-14.76%-12.36%-47.71%-30.88%-9.12%
FCF Yield
-12.76%-14.70%-11.61%-29.75%-29.45%-7.00%
Buyback Yield / Dilution
-25.67%-29.12%-23.52%-11.79%-13.32%-173.68%
SEC Filings: 10-K · 10-Q